Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action.
Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, Van den Heede K, Roobrouck A, Grot E, Kent TC, Laeremans T, Steffensen S, Van Heeke G, Brown Z, Charlton SJ, Cromie KD.
Bradley ME, et al. Among authors: kent tc.
Mol Pharmacol. 2015 Feb;87(2):251-62. doi: 10.1124/mol.114.094821. Epub 2014 Dec 2.
Mol Pharmacol. 2015.
PMID: 25468882